By: PRISM Mediawire
March 19, 2026
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption
Initial CLARITY trial readout in Q4 2026
Strong Balance Sheet with Cash Runway into 2028
Broomfield, CO, March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company’s recent momentum and value-creating priorities for 2026.
The letter highlights Aclarion’s continued momentum in expanding adoption of its Nociscan platform, growing clinical evidence, and advancing reimbursement initiatives in both the United Kingdom and the United States. The update also highlights the company’s ongoing CLARITY clinical trial, expansion of commercial engagement with physicians and imaging centers, and its strong balance sheet supporting continued execution.
“Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business,” said Brent Ness, Chief Executive Officer of Aclarion. “With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.”
The full CEO Shareholder Letter is available on the company’s website.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, an initial interim data readout is expected later in 2026, followed by the public disclosure of early interim results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
Media Contacts:
Jennie Kim
SPRIG Consulting
Source: Aclarion, Inc.
The latest news and updates relating to $ACON are available in the company’s newsroom at: https://tinyurl.com/aconnewsroom
PMW on Newsramp: https://newsramp.com/newswire/prism
Add PRISM MediaWire as your preferred news source on Google
The post Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts first appeared on Prism Media Wire.
This contant was orignally distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts.
